Aclaris Therapeutics ATI-052 Posts Early Eczema, Asthma Signals in Phase 1b

Aclaris Therapeutics ATI-052 Posts Early Eczema, Asthma Signals in Phase 1b

Aclaris Therapeutics (NASDAQ:ACRS) reported Phase 1b proof-of-concept results for ATI-052, its bispecific antibody designed to inhibit thymic stromal lymphopoietin (TSLP) and IL-4 receptor alpha, in small studies of atopic dermatitis and asthma. The company said the treatment was well tolerated and

Aclaris reports positive results for POC trial of antibody in dermatitis and asthma - BioTuesdays

Aclaris Therapeutics (NASDAQ: ACRS) has announced positive primary analysis results from the Phase 1b proof-of-concept (POC) trials of its anti-TSLP/IL-4Rα bispecific antibody ATI-052 in atopic dermatitis and asthma. According to Aclaris, both trials demonstrated strong proof-of-concept with rapid and broad responses to ATI-052, further validating the additive/synergistic potential of simultaneously targeting TSLP, IL-4, and IL-13 […]